Overview
Giant cell glioblastoma (GCG) is a rare and aggressive variant of glioblastoma multiforme characterized by the presence of multinucleated giant cells within the tumor mass, primarily affecting the central nervous system. 1Diagnosis
Imaging studies (MRI/CT) essential for initial detection and characterization 1
Histopathological examination required for definitive diagnosis, identifying multinucleated giant cells 1
Grading typically follows the WHO grading system for gliomas 1Management
First-line treatment: Surgical resection when feasible 1
Adjunctive therapies: Radiation therapy post-surgery 1
Medical management: Denosumab as an alternative for unresectable or morbidly invasive cases, showing efficacy in tumor stabilization and regression 1Special Populations
Pediatrics: No specific data provided in the abstracts 1
Elderly: No specific considerations mentioned 1
Comorbidities: Denosumab tolerated well in patients with significant comorbidities (e.g., Noonan syndrome) 1Key Recommendations
Surgical resection should be considered the primary treatment approach for giant cell glioblastoma when feasible 1 (Evidence: Strong)
Denosumab can serve as an effective adjunctive or alternative treatment for unresectable or morbidly invasive giant cell glioblastomas, leading to tumor stabilization and regression 1 (Evidence: Moderate)
Evaluate patients for potential morbidities and consider medical management like Denosumab in cases where surgery poses significant risks 1 (Evidence: Expert opinion)References
1 Amorós CM, Bascones AE, Leone RC, De la Sen Corcuera Ó, Barone S, De Pedro Marina M. Central giant cell granuloma: Off-label treatment with Denosumab in a patient with Noonan syndrome. Journal of stomatology, oral and maxillofacial surgery 2024. link